INMB — INmune Bio, Inc.

INmune Bio Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Net Loss: Approximately $6.5 million for Q3 2025, down from $12.1 million in Q3 2024.
• Research and Development Expenses: Approximately $4.9 million, reduced from $10.1 million year-over-year.
• General and Administrative Expenses: Approximately $2.5 million, slightly up from $2.2 million in the prior year.
• Cash Position: As of September 30, 2025, cash and cash equivalents totaled approximately $27.7 million, sufficient to fund operations into Q4 2026.
• Shares Outstanding: Approximately 26.6 million shares as of October 30, 2025.

2. Strategic Updates and Business Highlights

• Leadership Transition: David Moss took over as CEO in July 2025, focusing on advancing the company’s drug development programs.
• CORDStrom Program: Preparing for marketing approval submissions in the U.K. and U.S. for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Positive trial results indicated significant benefits, particularly in reducing itch and improving quality of life.
• XPro Platform: Aiming to treat neuroinflammation in Alzheimer's disease. A manuscript detailing Phase II MINDFuL trial results has been submitted for peer review, with promising findings in patients with higher baseline inflammation.
• INKmune: Completed a Phase II trial in prostate cancer ahead of schedule, meeting primary and two secondary endpoints.

3. Forward Guidance and Outlook

• Upcoming Milestones:
  • Q4 2025: Additional data from CORDStrom trials expected.
  • Mid-2026: Anticipated filing of a marketing authorization application (MAA) in the U.K. and a biologics licensing application (BLA) in the U.S.
  • Q1 2026: Expected clarity on the accelerated regulatory pathway for XPro and results from imaging data.
• 2026 Outlook: Anticipated as a pivotal year with multiple regulatory submissions and data releases.

4. Bad News, Challenges, or Points of Concern

• Regulatory Delays: The end of Phase II meeting with the FDA for XPro has been pushed to Q1 2026 due to delays in data preparation.
• Market Competition: CORDStrom will face competition from existing therapies in RDEB, particularly regarding pricing and efficacy.
• Clinical Trial Risks: The complexities of drug development, especially in rare diseases, pose inherent risks that could impact timelines and outcomes.

5. Notable Q&A Insights

• XPro Regulatory Alignment: Key questions for the FDA meeting will focus on the registration study setup, enrichment biomarkers, and safety database requirements.
• Partnership Discussions: Current discussions for potential partnerships are cautious, awaiting more comprehensive datasets and regulatory feedback.
• Future of INKmune: The company plans to gather more Phase II data before deciding on partnerships, with a focus on randomized trials in prostate cancer and potentially other indications.
• CORDStrom's Unique Position: The platform's ability to provide systemic treatment for RDEB and its potential for other diseases was emphasized, highlighting its differentiation from existing therapies.

This summary encapsulates the key financial metrics, strategic initiatives, forward guidance, challenges, and insights from the Q&A session, providing a balanced view of INmune Bio's current status and future direction.